About Boehringer Ingelheim
Boehringer Ingelheim is a German multinational, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885 by Albert Boehringer, the company is one of the world’s largest privately owned pharmaceutical companies and remains family-owned after more than 140 years. Unlike many global pharmaceutical firms, Boehringer Ingelheim is not publicly traded, allowing it to focus on long-term research and innovation rather than short-term shareholder returns.
Overview
| Attribute | Details |
|---|---|
| Founded | 1885 |
| Founder | Albert Boehringer |
| Headquarters | Ingelheim am Rhein, Germany |
| Company Type | Private, family-owned |
| Industry | Biopharmaceuticals & Animal Health |
| Employees | Over 54,000 worldwide (2025) |
| Global Presence | Operations in more than 130 markets |
| Core Businesses | Human Pharmaceuticals, Animal Health, Biopharmaceutical Contract Manufacturing |
History
Boehringer Ingelheim was established in 1885 as a small chemical manufacturing company in Ingelheim, Germany. At its founding, it employed only 28 people [1].
During the 20th century, the company expanded internationally while remaining under family ownership. Major milestones include:
- 1885 – Company founded by Albert Boehringer.
- 1948 – First international subsidiary opened in Vienna, Austria.
- 1955 – Official launch of the Animal Health division.
- 1980s–2000s – Rapid expansion into global pharmaceutical research.
- 2017 – Acquisition of Merial, significantly strengthening its Animal Health business [3].
- Today – Recognized as one of the world’s leading research-driven biopharmaceutical companies.
Business Segments
1. Human Pharmaceuticals
This is the company’s largest business area. Boehringer Ingelheim develops innovative medicines for diseases with significant unmet medical needs.
Major therapeutic areas include:
- Cardiovascular disease
- Respiratory diseases
- Metabolic disorders
- Oncology (Cancer)
- Immunology
- Mental health and central nervous system disorders
- Kidney disease
The company invests billions of euros annually into research and development [2].
2. Animal Health
Boehringer Ingelheim is among the world’s largest animal health companies.
Products include:
- Vaccines
- Parasite prevention
- Livestock medicines
- Companion animal treatments
- Veterinary diagnostics
The business serves:
- Dogs
- Cats
- Horses
- Cattle
- Swine
- Poultry
The acquisition of Merial in 2017 made Boehringer Ingelheim one of the global leaders in veterinary medicine [3].
3. Biopharmaceutical Contract Manufacturing
The company also manufactures biological medicines for other pharmaceutical companies.
Services include:
- Cell line development
- Bioprocess development
- Commercial manufacturing
- Regulatory support
This division supports biotechnology and pharmaceutical partners worldwide.
Research & Innovation
Boehringer Ingelheim is recognized as a research-intensive company. Its R&D focuses on discovering first-in-class or breakthrough therapies, particularly in areas where existing treatments are inadequate.
Current research priorities include:
- Obesity
- Fibrosis
- Cardiovascular diseases
- Diabetes
- Cancer
- Rare diseases
- Respiratory medicine
- Digital health
The company collaborates extensively with universities, hospitals, startups, and biotechnology firms [2].
Major Products
Some of Boehringer Ingelheim’s best-known medicines include:
Human Medicines
- Jardiance® (empagliflozin) – Type 2 diabetes, heart failure, and chronic kidney disease
- Ofev® (nintedanib) – Idiopathic pulmonary fibrosis and other fibrosing lung diseases
- Pradaxa® (dabigatran) – Blood thinner for stroke prevention and thromboembolism
- Spiriva® (tiotropium) – Chronic obstructive pulmonary disease (COPD) and asthma
- Aptivus® – HIV treatment
Animal Health
- NexGard® – Flea and tick prevention
- Heartgard® – Heartworm prevention
- Vetmedin® – Heart disease treatment in dogs
- Ingelvac® vaccines for livestock
Global Presence
Boehringer Ingelheim operates in:
- Europe
- North America
- Latin America
- Asia-Pacific
- Middle East
- Africa
The company has manufacturing facilities, research centers, regional headquarters, and commercial offices across more than 130 markets worldwide.
Corporate Culture
Because the company remains privately owned, it emphasizes:
- Long-term thinking
- Scientific excellence
- Sustainability
- Innovation
- Employee development
- Ethical business practices
- Patient-centered research
Its stated purpose is to transform lives through breakthrough therapies while improving the health of both people and animals.
Sustainability
The company invests in:
- Reducing greenhouse gas emissions
- Responsible sourcing
- Biodiversity initiatives
- Access to medicines
- Animal welfare
- Diversity and inclusion
- Community health programs
These initiatives form part of its broader environmental, social, and governance (ESG) strategy.
Awards & Reputation
Boehringer Ingelheim is widely recognized for:
- Strong investment in research and development
- Leadership in respiratory medicine
- Significant presence in animal health
- Family-owned governance model
- Long-term business stability
It is frequently ranked among the world’s leading pharmaceutical companies by revenue and research investment [2].
Key Facts
- Founded: 1885
- Founder: Albert Boehringer
- Headquarters: Ingelheim am Rhein, Germany
- Ownership: Family-owned (private)
- Employees: 54,000+ globally
- Business Areas: Human Pharmaceuticals, Animal Health, Biopharmaceutical Contract Manufacturing
- Global Reach: 130+ markets
- Core Focus: Research-driven innovation for human and animal health
Mission
Boehringer Ingelheim’s mission is to develop breakthrough therapies that transform lives for current and future generations, focusing on diseases where patients still have significant unmet medical needs while advancing preventive care in animal health [2].
